Earnings Feed
Start Free
Home/Filings/4/0001171843-15-005296
4//SEC Filing

Xenon Pharmaceuticals Inc. 4

Accession 0001171843-15-005296

$XENECIK 0001582313operating
View on SEC.govCompany Profile

Filed

Sep 23, 8:00 PM ET

Accepted

Sep 24, 9:56 PM ET

Size

58.5 KB

Accession

0001171843-15-005296

Insider Transaction Report

Form 4
Period: 2015-09-22
Xenon Pharmaceuticals Inc.XENE
GOLDBERG Y. PAUL
VP of Clinical Development
Transactions
  • Tax Payment

    Common Shares

    2015-09-22$9.53/sh−198$1,887→ 6,316 total
  • Exercise/Conversion

    Common Shares

    2015-09-22$3.77/sh+1,028$3,876→ 8,791 total
  • Tax Payment

    Common Shares

    2015-09-22$9.53/sh−305$2,907→ 8,486 total
  • Tax Payment

    Common Shares

    2015-09-22$9.53/sh−1,525$14,533→ 12,105 total
  • Exercise/Conversion

    Common Shares

    2015-09-22$3.56/sh+6,172$21,972→ 18,277 total
  • Tax Payment

    Common Shares

    2015-09-22$9.53/sh−1,829$17,430→ 16,448 total
  • Exercise/Conversion

    Common Shares

    2015-09-22$3.52/sh+3,703$13,035→ 20,151 total
  • Tax Payment

    Common Shares

    2015-09-22$9.53/sh−1,687$16,077→ 27,531 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2015-09-22−7,973→ 4,372 total
    Exercise: $2.68Exp: 2022-12-31→ Common Shares (7,973 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2015-09-22−785→ 243 total
    Exercise: $2.68Exp: 2022-12-31→ Common Shares (785 underlying)
  • Tax Payment

    Common Shares

    2015-09-22$9.53/sh−1,098$10,464→ 19,053 total
  • Tax Payment

    Common Shares

    2015-09-22$9.53/sh−923$8,796→ 21,245 total
  • Exercise/Conversion

    Common Shares

    2015-09-22$2.68/sh+7,973$21,368→ 29,218 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2015-09-22−6,172→ 0 total
    Exercise: $3.56Exp: 2019-12-31→ Common Shares (6,172 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2015-09-22−3,115→ 1,000 total
    Exercise: $3.73Exp: 2020-12-01→ Common Shares (3,115 underlying)
  • Exercise/Conversion

    Common Shares

    2015-09-22$3.07/sh+5,144$15,792→ 13,630 total
  • Exercise/Conversion

    Common Shares

    2015-09-22$3.73/sh+3,115$11,619→ 22,168 total
  • Sale

    Common Shares

    2015-09-23$9.02/sh−4,000$36,080→ 18,000 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2015-09-22−2,057→ 0 total
    Exercise: $3.21Exp: 2016-12-31→ Common Shares (2,057 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2015-09-22−3,703→ 0 total
    Exercise: $3.52Exp: 2020-07-01→ Common Shares (3,703 underlying)
  • Exercise/Conversion

    Common Shares

    2015-09-22$5.22/sh+411$2,145→ 6,514 total
  • Tax Payment

    Common Shares

    2015-09-22$9.53/sh−610$5,813→ 7,763 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2015-09-22−411→ 0 total
    Exercise: $5.22Exp: 2015-12-31→ Common Shares (411 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2015-09-22−5,144→ 0 total
    Exercise: $3.07Exp: 2018-12-31→ Common Shares (5,144 underlying)
  • Exercise/Conversion

    Common Shares

    2015-09-22$2.68/sh+785$2,104→ 28,316 total
  • Tax Payment

    Common Shares

    2015-09-22$9.53/sh−167$1,592→ 28,149 total
  • Sale

    Common Shares

    2015-09-22$9.33/sh−6,149$57,384→ 22,000 total
  • Sale

    Common Shares

    2015-09-24$8.60/sh−12,000$103,200→ 6,000 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2015-09-22−1,028→ 0 total
    Exercise: $3.77Exp: 2017-12-31→ Common Shares (1,028 underlying)
  • Exercise/Conversion

    Common Shares

    2015-09-22$3.21/sh+2,057$6,603→ 8,373 total
Footnotes (16)
  • [F1]The exercise price was converted from $6.07 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.
  • [F10]The shares subject to the option fully vested on December 31, 2011.
  • [F11]The shares subject to the option fully vested on December 31, 2012.
  • [F12]The shares subject to the option fully vested on December 31, 2013.
  • [F13]The shares subject to the option fully vested on June 30, 2014.
  • [F14]The shares subject to the option fully vested on November 30, 2014.
  • [F15]25% of the shares subject to the Option vested on the one year anniversary of January 1, 2013 (the "Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the Vesting Commencement Date.
  • [F16]One-third of the shares subject to the Option vested on January 1, 2013 (the "Vesting Commencement Date") and the remaining two-thirds of the shares subject to the Option vest in equal monthly installments on each monthly anniversary of the Vesting Commencement Date over the following four years.
  • [F2]Represents the closing price of the Company's common shares on September 21, 2015, converted to a Canadian dollar amount for purposes of net settlement calculations.
  • [F3]The exercise price was converted from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.
  • [F4]The exercise price was converted from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.
  • [F5]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $9.15 to $9.53, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  • [F6]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  • [F7]The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.715, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
  • [F8]The shares subject to the option fully vested on December 31, 2009.
  • [F9]The shares subject to the option fully vested on December 31, 2010.

Documents

1 file

Issuer

Xenon Pharmaceuticals Inc.

CIK 0001582313

→
Entity typeoperating
IncorporatedBritish Columbia, Canada

Related Parties

1
  • filerCIK 0001582313

Filing Metadata

Form type
4
Filed
Sep 23, 8:00 PM ET
Accepted
Sep 24, 9:56 PM ET
Size
58.5 KB
View on SEC.gov